KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 105 filers reported holding KEROS THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,938,466 | -2.1% | 405,849 | +23.4% | 0.00% | 0.0% |
| Q2 2023 | $13,215,202 | -16.9% | 328,900 | -11.7% | 0.00% | 0.0% |
| Q1 2023 | $15,909,294 | -21.8% | 372,583 | -12.1% | 0.00% | -40.0% |
| Q4 2022 | $20,354,285 | +19.2% | 423,871 | -6.6% | 0.01% | +25.0% |
| Q3 2022 | $17,077,000 | +66.2% | 453,907 | +22.1% | 0.00% | +33.3% |
| Q2 2022 | $10,275,000 | -34.2% | 371,854 | +29.4% | 0.00% | 0.0% |
| Q1 2022 | $15,621,000 | -12.0% | 287,261 | -5.3% | 0.00% | 0.0% |
| Q4 2021 | $17,746,000 | +63.5% | 303,302 | +10.6% | 0.00% | +50.0% |
| Q3 2021 | $10,852,000 | +116.7% | 274,325 | +132.6% | 0.00% | +100.0% |
| Q2 2021 | $5,009,000 | -36.4% | 117,948 | -7.8% | 0.00% | -50.0% |
| Q1 2021 | $7,873,000 | -58.5% | 127,925 | -52.5% | 0.00% | -60.0% |
| Q4 2020 | $18,992,000 | +221.8% | 269,243 | +71.1% | 0.01% | +150.0% |
| Q2 2020 | $5,901,000 | – | 157,333 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 396,911 | $21,584,000 | 5.10% |
| Deep Track Capital, LP | 1,380,306 | $75,061,000 | 4.81% |
| Opaleye Management Inc. | 265,750 | $14,451,000 | 4.49% |
| Octagon Capital Advisors LP | 340,214 | $18,501,000 | 4.00% |
| First Light Asset Management, LLC | 658,145 | $35,790,000 | 3.16% |
| Altium Capital Management LP | 126,000 | $6,852,000 | 2.29% |
| Nantahala Capital Management | 816,830 | $44,419,000 | 1.96% |
| Orbimed Advisors | 1,679,417 | $91,327,000 | 1.48% |
| CHI Advisors LLC | 62,229 | $3,384,000 | 1.44% |
| Parkman Healthcare Partners LLC | 72,690 | $3,953,000 | 1.16% |